DK3684344T3 - Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf - Google Patents

Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf

Info

Publication number: DK3684344T3
Authority: DK; Denmark
Prior art keywords: deferiprone; delayed; methods; release tablets; tablets
Prior art date: 2017-10-25

Application number

DK18871663.3T

Other languages

English (en)

Inventor

Michael Spino

Bernard Charles Sherman

Original Assignee

Chiesi Farm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-25

Filing date

2018-10-25

Publication date

2025-08-04

2018-10-25 Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa

2025-08-04 Application granted granted Critical

2025-08-04 Publication of DK3684344T3 publication Critical patent/DK3684344T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Hematology (AREA)
Psychology (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Toxicology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK18871663.3T 2017-10-25 2018-10-25 Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf DK3684344T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762577055P	2017-10-25	2017-10-25
US201762596043P	2017-12-07	2017-12-07
PCT/IB2018/058350 WO2019082128A1 (en)	2017-10-25	2018-10-25	DELAYED-RELEASE RELEASE TABLETS AND METHODS OF USE

Publications (1)

Publication Number	Publication Date
DK3684344T3 true DK3684344T3 (da)	2025-08-04

Family

ID=66170815

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18871663.3T DK3684344T3 (da)	2017-10-25	2018-10-25	Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf

Country Status (29)

Country	Link
US (8)	US20200253945A1 (da)
EP (2)	EP4635573A2 (da)
JP (1)	JP7246384B2 (da)
KR (1)	KR102624627B1 (da)
CN (2)	CN114533689A (da)
AU (1)	AU2018357350B2 (da)
BR (1)	BR112020008128A2 (da)
CA (2)	CA3077514C (da)
DK (1)	DK3684344T3 (da)
ES (1)	ES3036967T3 (da)
FI (1)	FI3684344T3 (da)
HR (1)	HRP20251151T1 (da)
IL (2)	IL321388A (da)
LT (1)	LT3684344T (da)
MA (1)	MA50201B1 (da)
MD (1)	MD3684344T2 (da)
MX (1)	MX2020004107A (da)
MY (1)	MY204588A (da)
NZ (2)	NZ787785A (da)
PH (1)	PH12020550815A1 (da)
PL (1)	PL3684344T3 (da)
PT (1)	PT3684344T (da)
RS (1)	RS67157B1 (da)
SA (1)	SA520411808B1 (da)
SG (1)	SG11202003153TA (da)
SI (1)	SI3684344T1 (da)
SM (1)	SMT202500358T1 (da)
UA (1)	UA126977C2 (da)
WO (1)	WO2019082128A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY204588A (en)	2017-10-25	2024-09-05	Chiesi Farm Spa	Delayed release deferiprone tablets and methods of using the same
US12016850B2 (en)	2022-04-11	2024-06-25	Chiesi Farmaceutici S.P.A.	Modified release pharmaceutical formulations comprising deferiprone
CA3248506A1 (en)	2022-04-11	2023-10-19	Chiesi Farmaceutici S.P.A.	MODIFIED-RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING DEFERIPRONE
US12016851B2 (en)	2022-04-11	2024-06-25	Chiesi Farmaceutici S.P.A.	Modified release pharmaceutical formulations comprising deferiprone
JP2025512012A (ja)	2022-04-11	2025-04-16	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	デフェリプロンを含む修飾放出医薬製剤
JP2025533226A (ja) *	2022-10-14	2025-10-03	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	デフェリプロンを含む修飾放出医薬製剤
WO2024240775A1 (en)	2023-05-25	2024-11-28	Chiesi Farmaceutici S.P.A.	Pharmaceutical dosage forms for pulsatile release

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI98343C (fi) *	1995-03-21	1997-06-10	Orion Yhtymae Oy	Peroraalinen formulaatio
US5747532A (en)	1995-11-21	1998-05-05	Medinox, Inc.	Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
GB9625638D0 (en)	1996-12-10	1997-01-29	Cenes Ltd	Therapeutic antioxidants for alzheimer's diease
WO2001049266A2 (en)	1999-12-30	2001-07-12	Gwathemy Judith K	Iron chelator delivery system
CA2313270C (en) *	2000-06-30	2011-09-13	Apotex Inc.	Use of deferiprone in treating and preventing iron-induced cardiac disease
WO2004006856A2 (en)	2002-07-12	2004-01-22	The Buck Institute For Research On Aging	Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
US7985422B2 (en)	2002-08-05	2011-07-26	Torrent Pharmaceuticals Limited	Dosage form
US8268352B2 (en)	2002-08-05	2012-09-18	Torrent Pharmaceuticals Limited	Modified release composition for highly soluble drugs
JP4757024B2 (ja)	2002-11-07	2011-08-24	テクニオンリサーチアンドディベラップメントファウンデイションリミテッド	神経保護鉄キレート剤及びそれを含む医薬組成物
EP1776118A2 (en)	2004-08-06	2007-04-25	Shiva Biomedical, LLC	Iron chelators for treating radiocontrast-associated renal dysfunction
GB0502475D0 (en) *	2005-02-07	2005-03-16	Sb Pharmco Inc	Novel compositions
ES2441065T3 (es)	2006-02-22	2014-01-31	Apotex Technologies Inc.	Uso de la deferiprona y métodos para tratar y/o prevenir la ataxia de Friedreich resultante del mal manejo intracelular de hierro
MX2009002236A (es) *	2006-08-30	2009-03-13	Jagotec Ag	Formulaciones de dosis oral de liberacion controlada que comrpenden un nucleo y una o mas capas de barrera.
US9744137B2 (en)	2006-08-31	2017-08-29	Supernus Pharmaceuticals, Inc.	Topiramate compositions and methods of enhancing its bioavailability
US20080138440A1 (en) *	2006-11-29	2008-06-12	Cormedix Inc.	Methods of diagnosing and alleviating gadolinium toxicity
CN101352438A (zh)	2007-07-25	2009-01-28	复旦大学	去铁酮及其制剂在制备防治蒽环类药物心脏毒性药物中的用途
WO2009129592A1 (en)	2008-04-25	2009-10-29	Apotex Technologies Inc.	Liquid formulation for deferiprone with palatable taste
AU2009260414A1 (en)	2008-05-30	2009-12-23	University Of Cincinnati	Use of zinc chelators to inhibit biofilm formation
WO2010005851A1 (en)	2008-07-08	2010-01-14	Xenon Pharmaceuticals Inc.	Combination therapy for treating iron disorders
WO2010014502A1 (en) *	2008-07-31	2010-02-04	Aptapharma, Inc.	Functionally coated breakable tablets
EP2206506A1 (en)	2008-12-18	2010-07-14	Bracco Imaging S.p.A	Probiotic formulations
KR20120078667A (ko)	2009-01-26	2012-07-10	마이클 스피노	철 관련 안질환의 치료 및 예방을 위한 데페리프론의 용도
US8603814B2 (en)	2009-07-20	2013-12-10	Rutgers The State University Of New Jersey	Method of inhibiting nonsense-mediated mRNA decay
WO2011032000A2 (en)	2009-09-10	2011-03-17	New York University	Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide
US8563035B2 (en) *	2010-05-05	2013-10-22	Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi	Oral tablet compositions of dexlansoprazole
KR20140026354A (ko)	2011-01-07	2014-03-05	메리온 리서치 Ⅲ 리미티드	경구 투여용 철의 제약 조성물
DE102011112898A1 (de) *	2011-09-08	2013-03-14	Charité - Universitätsmedizin Berlin	Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen
JP2014533697A (ja)	2011-11-18	2014-12-15	アポテックステクノロジーズインコーポレイテッドＡｐｏｔｅｘＴｅｃｈｎｏｌｏｇｉｅｓＩｎｃ．	デフェリプロンを用いた処置方法
WO2013139931A1 (en)	2012-03-21	2013-09-26	Icm (Institut Du Cerveau Et De La Moelle Épinière)	Composition for use in the treatment of neurodegenerative diseases with parkinsonian syndromes
CA2885394A1 (en) *	2012-11-12	2014-05-15	Cipla Limited	Fixed dose pharmaceutical composition comprising deferasirox and deferipone
SG11201509308TA (en) *	2013-05-10	2015-12-30	Cipla Ltd	Low dose pharmaceutical composition
BR112015029468A8 (pt) *	2013-06-06	2020-03-17	Amip Llc	sistemas de dosagem oralmente administráveis, método para suplementar a nutrição de ferro em um indivíduo humano e métodos para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido
ITMI20132066A1 (it)	2013-12-11	2015-06-12	Farmatron Ltd	Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali
WO2018027132A1 (en)	2016-08-05	2018-02-08	Abfero Pharmaceuticals, Inc.	Dosing regimens for treating metal-mediated conditions
US20180362228A1 (en)	2017-02-16	2018-12-20	Jeffrey D. Jacobson	Container closure with integrated utensil
MY204588A (en)	2017-10-25	2024-09-05	Chiesi Farm Spa	Delayed release deferiprone tablets and methods of using the same

2018
- 2018-10-25 MY MYPI2020002003A patent/MY204588A/en unknown
- 2018-10-25 EP EP25186255.3A patent/EP4635573A2/en active Pending
- 2018-10-25 KR KR1020207014502A patent/KR102624627B1/ko active Active
- 2018-10-25 MD MDE20200792T patent/MD3684344T2/ro unknown
- 2018-10-25 CA CA3077514A patent/CA3077514C/en not_active Expired - Fee Related
- 2018-10-25 PT PT188716633T patent/PT3684344T/pt unknown
- 2018-10-25 NZ NZ787785A patent/NZ787785A/en unknown
- 2018-10-25 CN CN202210164525.3A patent/CN114533689A/zh active Pending
- 2018-10-25 ES ES18871663T patent/ES3036967T3/es active Active
- 2018-10-25 JP JP2020523267A patent/JP7246384B2/ja active Active
- 2018-10-25 AU AU2018357350A patent/AU2018357350B2/en active Active
- 2018-10-25 SI SI201831250T patent/SI3684344T1/sl unknown
- 2018-10-25 US US16/759,254 patent/US20200253945A1/en not_active Abandoned
- 2018-10-25 PL PL18871663.3T patent/PL3684344T3/pl unknown
- 2018-10-25 SM SM20250358T patent/SMT202500358T1/it unknown
- 2018-10-25 IL IL321388A patent/IL321388A/en unknown
- 2018-10-25 WO PCT/IB2018/058350 patent/WO2019082128A1/en not_active Ceased
- 2018-10-25 CA CA3172668A patent/CA3172668A1/en not_active Withdrawn
- 2018-10-25 UA UAA202003078A patent/UA126977C2/uk unknown
- 2018-10-25 LT LTEPPCT/IB2018/058350T patent/LT3684344T/lt unknown
- 2018-10-25 DK DK18871663.3T patent/DK3684344T3/da active
- 2018-10-25 US US16/171,170 patent/US10940116B2/en active Active
- 2018-10-25 CN CN201880069331.7A patent/CN111918646B/zh active Active
- 2018-10-25 MX MX2020004107A patent/MX2020004107A/es unknown
- 2018-10-25 SG SG11202003153TA patent/SG11202003153TA/en unknown
- 2018-10-25 RS RS20250792A patent/RS67157B1/sr unknown
- 2018-10-25 BR BR112020008128-0A patent/BR112020008128A2/pt unknown
- 2018-10-25 FI FIEP18871663.3T patent/FI3684344T3/fi active
- 2018-10-25 EP EP18871663.3A patent/EP3684344B1/en active Active
- 2018-10-25 NZ NZ763555A patent/NZ763555A/en unknown
- 2018-10-25 US US16/171,173 patent/US10780055B2/en active Active
- 2018-10-25 HR HRP20251151TT patent/HRP20251151T1/hr unknown
- 2018-10-25 MA MA50201A patent/MA50201B1/fr unknown
2019
- 2019-12-13 US US16/714,520 patent/US11458103B2/en active Active
2020
- 2020-04-03 US US16/839,928 patent/US11357731B2/en active Active
- 2020-04-13 IL IL273955A patent/IL273955B2/en unknown
- 2020-04-20 PH PH12020550815A patent/PH12020550815A1/en unknown
- 2020-04-21 SA SA520411808A patent/SA520411808B1/ar unknown
- 2020-05-12 US US15/930,373 patent/US10940115B2/en active Active
2021
- 2021-05-21 US US17/327,135 patent/US11723874B2/en active Active
2022
- 2022-05-12 US US17/742,960 patent/US11607389B2/en active Active

Also Published As

Publication number	Publication date
CN111918646A (zh)	2020-11-10
US10940115B2 (en)	2021-03-09
ES3036967T3 (en)	2025-09-25
FI3684344T3 (fi)	2025-10-08
US11607389B2 (en)	2023-03-21
IL321388A (en)	2025-08-01
US11458103B2 (en)	2022-10-04
MD3684344T2 (ro)	2025-09-30
WO2019082128A1 (en)	2019-05-02
IL273955B2 (en)	2025-11-01
HRP20251151T1 (hr)	2025-12-05
IL273955A (en)	2020-05-31
US10940116B2 (en)	2021-03-09
US20200268672A1 (en)	2020-08-27
SG11202003153TA (en)	2020-05-28
AU2018357350B2 (en)	2023-09-21
PH12020550815A1 (en)	2021-07-05
US20220265559A1 (en)	2022-08-25
NZ787785A (en)	2025-11-28
SA520411808B1 (ar)	2023-02-16
EP3684344A1 (en)	2020-07-29
EP4635573A2 (en)	2025-10-22
UA126977C2 (uk)	2023-03-01
PL3684344T3 (pl)	2025-10-27
NZ763555A (en)	2022-07-01
US20210386677A1 (en)	2021-12-16
US11723874B2 (en)	2023-08-15
PT3684344T (pt)	2025-08-04
BR112020008128A2 (pt)	2020-11-03
EP3684344A4 (en)	2020-11-18
US20190117581A1 (en)	2019-04-25
US20190125682A1 (en)	2019-05-02
EP3684344B1 (en)	2025-07-02
SMT202500358T1 (it)	2025-11-10
LT3684344T (lt)	2025-09-10
CN114533689A (zh)	2022-05-27
MA50201B1 (fr)	2025-07-31
KR102624627B1 (ko)	2024-01-16
CA3077514C (en)	2022-10-11
KR20200077542A (ko)	2020-06-30
CA3172668A1 (en)	2019-05-02
US20200188309A1 (en)	2020-06-18
MA50201A (fr)	2021-04-28
SI3684344T1 (sl)	2025-09-30
US11357731B2 (en)	2022-06-14
IL273955B1 (en)	2025-07-01
MX2020004107A (es)	2020-07-24
US20200253945A1 (en)	2020-08-13
RS67157B1 (sr)	2025-09-30
AU2018357350A1 (en)	2020-04-30
CA3077514A1 (en)	2019-05-02
MY204588A (en)	2024-09-05
JP2021500377A (ja)	2021-01-07
US10780055B2 (en)	2020-09-22
CN111918646B (zh)	2022-02-22
JP7246384B2 (ja)	2023-03-27
US20200237674A1 (en)	2020-07-30

Publication	Publication Date	Title
DK3774789T3 (da)	2025-06-10	BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3464282T3 (da)	2020-07-27	Heteroarylsubstituerede pyridiner og fremgangsmåder til anvendelse
DK3788044T3 (da)	2023-10-02	RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
DK3658557T3 (da)	2024-07-29	Tyk2-inhibitorer og anvendelser deraf
DK3317284T3 (da)	2020-01-13	Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3601358T5 (da)	2024-09-02	Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3618863T3 (da)	2023-08-21	Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3259597T3 (da)	2022-05-09	Pvrig-polypeptider og fremgangsmåder til behandling
DK3436048T3 (da)	2025-09-15	Neoantigener og fremgangsmåder til anvendelse deraf
DK3453707T3 (da)	2022-05-09	Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf
DK3486242T3 (da)	2022-01-10	Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf
DK3684344T3 (da)	2025-08-04	Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf
DK3353210T3 (da)	2025-01-06	Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3548033T3 (da)	2024-07-15	Forbindelser og deres fremgangsmåde til anvendelse
DK3710430T3 (da)	2024-09-09	Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
DK3356404T3 (da)	2021-10-25	Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3529257T3 (da)	2023-08-07	Oxysteroler og fremgangsmåder til anvendelse deraf
DK3303386T3 (da)	2024-10-28	Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
DK4105223T3 (da)	2025-07-07	Oxysteroler og fremgangsmåder til anvendelse deraf
DK3394065T3 (da)	2021-05-31	Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3828194T3 (da)	2025-06-30	Oxysteroler og fremgangsmåder til anvendelse deraf
DK3426781T3 (da)	2024-09-30	Mikro-rna'er og fremgangsmåder til anvendelse deraf
DK3525583T3 (da)	2025-10-27	Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3514151T3 (da)	2025-07-21	Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf
DK3089971T3 (da)	2020-08-31	Forbindelser og fremgangsmåder til anvendelse